

KRAVIS HENRY R  
Form 4  
November 14, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KKR Biosimilar L.P.

(Last) (First) (Middle)

C/O KOHLBERG KRAVIS  
ROBERTS & CO., L.P., 9 WEST  
57TH STREET, SUITE 4200

(Street)

NEW YORK, NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Coherus BioSciences, Inc. [CHRS]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/12/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code V                         | Amount  | (A) or (D) Price  |  |  |
| Common Stock                    | 11/12/2014                           |  | C                              | 2,499,499   | A <u>(1)</u> 2,499,499  | I  | See footnote <u>(2)</u>                    |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: KRAVIS HENRY R - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |              |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title        | Amount or Number of Shares |
| Series C Preferred Stock                   | (1)  | 11/12/2014                           |  | C                              | 2,499,499   | (1)  | (3)   | Common Stock | 2,499,499                  |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| KKR Biosimilar L.P.<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019      |               | X         |         |       |
| KKR Biosimilar GP LLC<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019    |               | X         |         |       |
| KKR Fund Holdings L.P.<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019   |               | X         |         |       |
| KKR Fund Holdings GP Ltd<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019 |               | X         |         |       |
| KKR Group Holdings L.P.<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019  |               | X         |         |       |
| KKR Group Ltd<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019            |               | X         |         |       |
| KKR & Co. L.P.<br>C/O KOHLBERG KRAVIS ROBERTS & CO.<br>L.P., 9 WEST 57TH STREET, SUITE 4200<br>NEW YORK, NY 10019           |               | X         |         |       |
|   |               | X         |         |       |

KKR Management LLC  
 C/O KOHLBERG KRAVIS ROBERTS & CO.  
 L.P., 9 WEST 57TH STREET, SUITE 4200  
 NEW YORK, NY 10019

KRAVIS HENRY R  
 C/O KOHLBERG KRAVIS ROBERTS & CO. X  
 L.P., 9 WEST 57TH STREET, SUITE 4200  
 NEW YORK, NY 10019

ROBERTS GEORGE R  
 C/O KOHLBERG KRAVIS ROBERTS & CO. X  
 L.P., 9 WEST 57TH STREET, SUITE 4200  
 NEW YORK, NY 10019

## Signatures

KKR BIOSIMILAR L.P. By: KKR Biosimilar GP LLC, its general partner By: /s/ Terence  
 Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief  
 Financial Officer 11/14/2014

\_\_Signature of Reporting Person Date

KKR BIOSIMILAR GP LLC By: /s/ Terence Gallagher Name: Terence Gallagher Title:  
 Attorney-in-fact for William J. Janetschek, Chief Financial Officer 11/14/2014

\_\_Signature of Reporting Person Date

KKR FUND HOLDINGS L.P. By: KKR Group Limited, the general partner of a general  
 partner By: /s/ Terence Gallagher Name: Terence Gallagher Title: Attorney-in-fact for  
 William J. Janetschek, Director 11/14/2014

\_\_Signature of Reporting Person Date

KKR FUND HOLDINGS GP LIMITED By: /s/ Terence Gallagher Name: Terence Gallagher  
 Title: Attorney-in-fact for William J. Janetschek, Director 11/14/2014

\_\_Signature of Reporting Person Date

KKR GROUP HOLDINGS L.P. By: KKR Group Limited, its general partner By: /s/ Terence  
 Gallagher Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek,  
 Director 11/14/2014

\_\_Signature of Reporting Person Date

KKR GROUP LIMITED By: /s/ Terence Gallagher Name: Terence Gallagher Title:  
 Attorney-in-fact for William J. Janetschek, Director 11/14/2014

\_\_Signature of Reporting Person Date

KKR & CO. L.P. By: KKR Management LLC, its general partner By: /s/ Terence Gallagher  
 Name: Terence Gallagher Title: Attorney-in-fact for William J. Janetschek, Chief Financial  
 Officer 11/14/2014

\_\_Signature of Reporting Person Date

KKR MANAGEMENT LLC By: /s/ Terence Gallagher Name: Terence Gallagher Title:  
 Attorney-in-fact for William J. Janetschek, Chief Financial Officer 11/14/2014

\_\_Signature of Reporting Person Date

HENRY R. KRAVIS By: /s/ Terence Gallagher Name: Terence Gallagher Title:  
 Attorney-in-fact 11/14/2014

Edgar Filing: KRAVIS HENRY R - Form 4

\_\_Signature of Reporting Person

Date

GEORGE R. ROBERTS By: /s/ Terence Gallagher Name: Terence Gallagher Title:  
Attorney-in-fact

11/14/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - (1) The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering.

Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.
  - (2) Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.
  - (3) Not applicable.

### Remarks:

The Reporting Persons may have been deemed to have been ten percent owners of the Issuer's common stock as calculated per

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.